Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005%, Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) With Plaque Psoriasis

NCT01563068 is registered in ClinicalTrials.gov with Mayne Pharma International Pty Ltd as lead sponsor.

NCT NCT01563068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01563068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005%, Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) With Plaque Psoriasis
Lead sponsor
Mayne Pharma International Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2012
Completion date
August 31, 2015
Enrollment
18 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis